An observational study in Subclinical Atherosclerosis and Cardiovascular Risk, sponsored by Infanta Leonor University Hospital. Active, not recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by Infanta Leonor University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 61 studies in Atherosclerosis with a site in Spain — 10 open to participants now, 25 under way, 12 of them phase 3. Atherosclerosis · Spain.
Among the 61 studies in Atherosclerosis with a site in Spain, this one is the 8th largest by planned enrollment of the 20 observational ones that give a count, is one of 2 that started in 2023, is one of 20 observational ones, reaches primary completion later than 2 of the 24 other live ones, and was the 59th registered.
1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.
Browse Atherosclerosis studies →10 of the 61 studies in Atherosclerosis with a site in Spain are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Spain, United States, Australia and 4 more countries
Ages 45–80
Instituto de Investigación Hospital Universitario La Paz · Sites in Spain
Ages 50+
Instituto de Investigación Marqués de Valdecilla · Sites in Spain
Ages 50+
Eli Lilly and Company · Sites in Spain, United States, Argentina and 25 more countries
Ages 18+
Instituto de Investigación Biomédica de Salamanca · Sites in Spain, France, Netherlands
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 164 Atherosclerosis studies recruiting now, 86 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
61 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 20 · Phase 4 3
First in 2004; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 884 is above the median of 250 across 526 observational studies indexed under Atherosclerosis.
Median enrollment 969 across the 41 interventional studies, 255 across the 20 observational. Of the 31 that completed or were terminated, 12 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 61 have an industry lead sponsor. The 10 most frequent:
Infanta Leonor University Hospital is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Infanta Leonor University Hospital has 1 study filed under Atherosclerosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Atherosclerosis with a site in Spain that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05202509Phase 3NewAmsterdam PharmaCardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease | 2026-11 |
| NCT07000123Phase 3AstraZenecaA Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event | 2027-01-11 |
| NCT05030428Phase 3Novartis PharmaceuticalsStudy of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease | 2027-05-10 |
| NCT06977295Instituto de Investigación Biomédica de SalamancaEvaluation of a Diagnostic Software for Coronary Artery Disease Using Retrospective CCTA Data (CODEX-1 Study) | 2026-11-30 |
| NCT06958315Novartis PharmaceuticalsInclisiran (Leqvio®) in Patients With Atherosclerotic Vascular Disease and/or Heterozygous Familial Hypercholesterolemia Treated in Spain: the INSPIRE Study | 2027-05-01 |
Add all 5 to your calendar (.ics) → With an account.
Among the 61 studies in Atherosclerosis with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Cardiovascular risk scores are widely used for risk stratification but may fail to identify a substantial proportion of individuals with subclinical atherosclerosis who are at increased risk of future cardiovascular events. Vascular ultrasound can directly detect carotid and femoral atherosclerotic plaques but its implementation is limited by the need for trained operators and expert interpretation. The AI-THEROSCOPE study aims to develop and validate an artificial intelligence-based tool capable of detecting subclinical atherosclerosis through the analysis of non-mydriatic retinal fundus images. Participants undergo clinical assessment, laboratory testing, carotid and femoral ultrasound, and retinal fundus photography. The performance of the AI model will be evaluated against vascular ultrasound findings as the reference standard for the presence of subclinical atherosclerosis.
Cardiovascular disease remains the leading cause of mortality worldwide. Current cardiovascular risk prediction models are useful for population-level risk estimation but may underestimate risk in a substantial proportion of individuals who already have subclinical atherosclerosis. Vascular ultrasound of the carotid and femoral arteries allows direct visualization of atherosclerotic plaques and improves cardiovascular risk stratification, but its widespread use is limited by the requirement for specialized equipment and trained personnel.
Retinal fundus imaging provides a non-invasive assessment of the microvasculature and has emerged as a promising tool for cardiovascular risk evaluation. Recent advances in artificial intelligence and deep learning have demonstrated the ability of retinal image analysis to identify cardiovascular risk factors and predict cardiovascular outcomes.
The AI-THEROSCOPE study is a prospective observational study designed to develop and validate an artificial intelligence model for the detection of subclinical atherosclerosis using non-mydriatic retinal fundus photographs. Adult participants without previous cardiovascular disease undergo standardized clinical evaluation, laboratory testing, carotid and femoral vascular ultrasound, and bilateral retinal fundus photography.
The presence of carotid and/or femoral atherosclerotic plaque assessed by vascular ultrasound serves as the reference standard. Deep learning techniques will be used to train and validate predictive models based on retinal images. Model performance will be evaluated using discrimination metrics including the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, positive predictive value, and negative predictive value.
The ultimate objective of the project is to develop a scalable, non-invasive, and easily deployable tool that may facilitate early detection of subclinical atherosclerosis and improve cardiovascular risk stratification in clinical practice and population screening programs.
Adults undergoing cardiovascular risk assessment at a university hospital cardiovascular risk unit and healthcare workers or relatives participating in cardiovascular screening programs. All participants undergo clinical evaluation, laboratory testing, carotid and femoral vascular ultrasound, and non-mydriatic retinal fundus photography.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adult participants without previous established cardiovascular disease who undergo standardized cardiovascular risk assessment, laboratory testing, bilateral carotid and femoral vascular ultrasound, and non-mydriatic retinal fundus photography. The cohort is used for the development and validation of an artificial intelligence model for the detection of subclinical atherosclerosis using retinal fundus images. The presence of carotid and/or femoral atherosclerotic plaque assessed by vascular ultrasound serves as the reference standard.
Area Under the Receiver Operating Characteristic Curve (AUC) for Detection of Subclinical Atherosclerosis
Diagnostic performance of the artificial intelligence model based on non-mydriatic retinal fundus images for detecting carotid and/or femoral atherosclerotic plaques, using vascular ultrasound as the reference standard.
Time frame: Baseline
Plan to share: No — Individual participant data (IPD) will not be publicly shared. De-identified data may be made available upon reasonable request to the principal investigator, subject to institutional policies, ethical approval, data protection regulations, and applicable legal requirements.
No publications or documents are linked to this record.
Ran from Oct 2023 to primary completion in Jan 2026, 27 months.
Of 145 non-industry observational studies under Atherosclerosis, half reached primary completion within 84 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 158. This study's 27 months is below that.
Counting every sponsor, half of 170 studies reached it within 62 months; a quarter within 31 and three quarters within 153.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Infanta Leonor University Hospital